Hemab Therapeutics, a Copenhagen, Denmark and Boston, MA-based clinical-stage biotechnology company developing prophylactic therapeutics for bleeding and thrombotic disorders, raised $135M in Series B funding.
The round was led by Access Biotechnology with participation from new investors Deep Track Capital, Avoro Ventures, Invus, Rock Springs Capital, and Maj Invest Equity, as well as all current investors Novo Holdings, RA Capital Management, and HealthCap. Hemab also announced Dan Becker, MD, PhD, Managing Director at Access, and Uya Chuluunbaatar, PhD, Partner at Avoro Ventures, will also join as Directors. Christine Borowski, PhD, Vice President at Access, will join as a Board Observer.
The company intends to use the funds to support the Phase 1/2 study of bispecific antibody HMB-001 in Glanzmann Thrombasthenia, continue of pivotal studies, complete of Phase 1/2 study of HMB-VWF in von Willebrand Disease, as well as future pipeline evolution.
Led by Benny Sorensen, MD, PhD, CEO & President, Hemab Therapeutics is a clinical-stage biotech company. It is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. Its strategic guidance, Hemab 1-2-5, targets the development of 5 clinical assets by 2025 to deliver innovation for patients with Factor VII Deficiency, Bernard Soulier Syndrome, Von Willebrand Disease, Hereditary Hemorrhagic Telangiectasia (or Osler-Weber-Rendu disease), and Congenital Antithrombin III Deficiency.